Migraine is a neurological condition characterized by moderate to severe headaches of variable frequency that can be highly disabling and lower quality of life. Although triptans have long dominated the market for prescription antimigraine therapies, many patients only partially respond, or do not respond, to triptans. Other patients cannot tolerate these therapies or are ineligible to receive them owing to cardiovascular contraindications. As a result, a clear opportunity exists for therapeutic alternatives. Since 2020, new nontriptan products have increased competition in the acute migraine therapy market; these agents include improved formulations of established drugs such as Impel Pharmaceuticals’ Trudhesa and agents with novel mechanisms of action such as AbbVie’s Ubrelvy and Pfizer’s Nurtec ODT (oral CGRP receptor antagonists). With more launches expected through 2024, this quantitative analysis of national patient-level claims data examines the growing uptake of new brands to treat both newly diagnosed and recently treated patients in a market with many generic therapy options.
Markets covered: United States.
Key companies: Pfizer, AbbVie, Eli Lilly, Scilex, Impel Pharmaceuticals, GlaxoSmithKline, Merck & Co.
Key drugs: Ubrelvy, Nurtec ODT, Reyvow, Elyxyb, Trudhesa, Zembrace SymTouch, Onzetra Xsail, sumatriptan, zolmitriptan, rizatriptan, and other FDA-approved acute antimigraine therapies
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.